Ladies and gentlemen, thank you for standing by and welcome to the Quarter Four 2014 China Pharma Holdings, Inc. Earnings Conference Call. At this time, all participants are in a listen-only mode. There will be a presentation followed by a question-and-answer session. [Operator Instructions]. I must advise you that this conference is being recorded today, 31st of March, 2015. I would now like to hand the conference over to your speaker today, Mr. Diana Hong. Please go ahead, ma’am.

Good morning ladies and gentlemen and good evening to those of you joining us from China. Welcome to China Pharma Holdings Fiscal Year 2014 Earnings Conference Call. I’m Diana Huang, the company’s Investor Relations Manager. Speaking on the call today are China Pharma President and CEO and Interim CFO, Ms. Zhilin Li and Corporate Vice President Mr. Sam Hsing. In addition, I will provide translation during the Q&A session of the call. The company’s earnings press release issued earlier this morning is available on our website at www.chinapharmaholdings.com. I’d like to remind our listeners that on this call management’s prepared remarks contain forward-looking statements, which are subject to risks and uncertainties and management may make additional forward-looking statements in response to your questions. Therefore, the company claims the protection of the Safe Harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act of 1995. Actual results may differ from those discussed today due to such risks as market and customer acceptance and demand for our products, our ability to market our products, the impact of competitive products and the pricing, the ability to develop and launch new products on a timely basis, the regulatory environment including government regulation in the PRC, our ability to obtain the requisite regulatory approvals to commercialize our products, fluctuations in operating result, including spending for research and development, and sales and marketing activities, and other risks detailed from time-to-time in our filings with the SEC. In addition, any projections as to the company’s future performance represent management’s estimates as of today, March 31, 2015. China Pharma assumes no obligation to update those projections in the future as market conditions change. Now it is my pleasure to turn the call over to China Pharma’s CEO and Interim CFO, Ms. Li to make her opening remarks in Chinese which will be translated by Sam. Afterwards, Sam will continue translating Ms. Li’s detailed discussion of the company’s fiscal year 2014 fiscal financial results.

Thank you, Diana, and good morning everyone. I would like to thank each of you for joining us today and for your continued support of China Pharma. We have experienced tough challenges and made remarkable achievements in 2014. We completed the construction of a 20,000 square meters new factory, installed with four sterilization production lines, two liquid injectables and two dry powder injectables production lines after nearly two years of construction. In November 2014, we obtained new GMP certificate issued by CFDA, as defined below and commenced the manufacturing at our dry powder injectables and liquid injectables production lines. While sustained the loss brought by once-in-forty-year 16 grade super typhoon during the period from January 1, 2014 to November 3, 2014; we suspended such two production lines as they did not then meet the GMP upgrading deadline. In this production-suspended period, we controlled our market by limiting our credit sales and executed a prudent marketing strategy and specifically by screening our existing and potential distributors and hospital customers based on their payment speed in order to gradually improve our trade turnover, especially in terms of the collection of our accounts receivables. This strategy has temporarily impacted our sales in the current period by limiting our credit sales. I will now read the rest of the miscellaneous prepared remarks in English. The Chinese pharmaceutical industry has been a key contributor to the PRC’s economic growth. The Chinese pharmaceutical market reached RMB 926.1 billion in 2012 according to Medical Blue Book, China Pharmaceutical Market Report 2012, the Blue Book published by the Chinese Academy of Social Sciences, CASS, on December 28, 2012. The compound growth rate of the China’s pharmaceutical market was over 20% from 2005 to 2010 and the Blue Book forecasts that it will continue its rapid expansion at an…

On behalf of the entire China Pharma team, we would like to thank you for your interest in the company and the participation on this call. For any of you traveling to China, we always welcome and encourage any visitors from our shareholders, potential investor and analysts. This concludes China Pharma’s fiscal year 2014 earnings call. Thanks.

Ladies and gentlemen, that does conclude our conference for today. Thank you for participating. You may all disconnect.